I-Corps: Commercialization of Radio-Carbon Analyzer for Biomedical Applications

I-Corps：生物医学应用放射性碳分析仪的商业化

• 批准号: 1443530
• 负责人: Daniel Murnick
• 金额: $ 5万
• 依托单位: Rutgers University Newark
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-07-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1443530&HistoricalAwards=false
• 关键词: Corps; Commercialization; Radio; Carbon; Analyzer

The team has developed a new method for ultrasensitive radiocarbon detection. The laser-based technology allows the measurement of trace amounts, on the order of one part per one trillion, of radioactive label in organic compounds. The proposed analyzer has the potential to change the way the pharmaceutical industry conducts metabolic and toxicity studies with radio-labeled carbon for its drug discovery and development programs long before human clinical trials. A commercialized version of this analyzer technology would enable scientists to conduct ultrasensitive measurements more quickly on-site and with small samples and thus less radioactivity.Existing Accelerator Mass Spectrometer technology effectively counts atoms as they are accelerated across a large equipment platform that takes up a large room and is expensive to maintain. It is complex and expensive; only a few such systems exist for the purposes of Biological Radiocarbon studies, and samples must be outsourced to such facilities with long turnaround times. Existing Liquid Scintillation Counter (LSC) technology must use samples 3-4 orders of magnitude larger with much higher radiation because the beta-decay counting technique lacks the sensitivity for many metabolic and toxicity studies. The proposed laser based technology effectively tickles the CO2 molecules with a laser millions of times per second in an electrical discharge and obtains an electronic response (known as the Optogalvanic Effect). The proposed technology has the potential to reduce the costs associated with new drug development by enabling pharmacokinetic studies to be initiated in humans sooner than currently possible and will thus accelerate the time to approval and market.

该团队开发了一种超灵敏放射性碳探测的新方法。这种基于激光的技术可以测量有机化合物中痕量的放射性标签，大约是一万亿分之一。在人体临床试验之前，该分析仪有可能改变制药行业使用放射性标记碳进行代谢和毒性研究的方式，用于药物发现和开发项目。这种分析仪技术的商业化版本将使科学家能够更快地在现场进行超灵敏的测量，并使用小样本，从而减少放射性。现有的加速器质谱仪技术有效地计数原子，因为它们在一个大型设备平台上加速，占用了一个大房间，维护成本很高。它既复杂又昂贵；用于生物放射性碳研究的这样的系统只有少数，而且样品必须外包给这样的设施，周转时间很长。现有的液体闪烁计数器（LSC）技术必须使用大3-4个数量级的样品和高得多的辐射，因为β衰变计数技术缺乏许多代谢和毒性研究的灵敏度。提出的基于激光的技术在放电中每秒数百万次有效地用激光挠CO2分子，并获得电子响应（称为光电效应）。拟议的技术有可能降低与新药开发相关的成本，使人体药代动力学研究能够比目前更快地开始，从而加快批准和上市的时间。